Kristian Reich

Universität Hamburg — Germany

Immunology and Microbiology · Life Sciences

103h-index41.9kcitations745works4.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Psoriasis: Treatment and Pathogenesis(482), Dermatology and Skin Diseases(352), Autoimmune Bullous Skin Diseases(120), Asthma and respiratory diseases(115), Pharmaceutical studies and practices(81)

Publications740 total

Efficacy of up to 4 years of tralokinumab in adults with moderate‐to‐severe atopic dermatitis
Journal of the European Academy of Dermatology and Venereology·2025Open Access
284 An Abrocitinib Surrogate Molecule Reduces Disease Severity and Protects Skin Barrier Integrity in a Humanized Mouse Model of Atopic Dermatitis Flare-Ups
Journal of Investigative Dermatology·2025
285 Abrocitinib impact on memory T cell subsets in Atopic Dermatitis: In vitro and ex vivo findings
Journal of Investigative Dermatology·2025Open Access
116 Decoding the IL-17 axis in hidradenitis suppurativa: Pharmacodynamic profiling of the Nanobody® sonelokimab reveals IL-19 and PI3 as biomarkers of IL-17 pathway activity
Journal of Investigative Dermatology·2025
117 Proteomic analysis of the Phase 2 MIRA trial population highlights IL-17 signaling and draining tunnel lesions as pivotal to systemic inflammation in hidradenitis suppurativa
Journal of Investigative Dermatology·2025Open Access
Investigation of the pivotal role of human Schwann cells and sensory neurons in perineural invasion (PNI) of PDAC
Pancreatology·2025
Sonelokimab, an IL-17A/IL-17F-inhibiting nanobody for active psoriatic arthritis: a randomized, placebo-controlled phase 2 trial
Nature Medicine·2025· 3 citedOpen Access
Effects of a Gel Containing the Defined Microalgae Extract Spiralin® on the Skin Microbiome and Clinical Activity in Atopic Dermatitis: A Double-Blind, Intraindividual Vehicle-Controlled Proof-Of-Concept Study
Skin Pharmacology and Physiology·2025Open Access
62297 Resolution of deep dermal inflammatory lesions with the Nanobody sonelokimab in moderate-to-severe hidradenitis suppurativa (HS): preclinical results and outcomes from the Phase 2 MIRA trial
Journal of the American Academy of Dermatology·2025
63435 Treatment with Abrocitinib reduces circulating, skin homing, and resident memory T-cells in atopic dermatitis samples in vitro and ex vivo, and severity of disease flares in a humanized mouse model
Journal of the American Academy of Dermatology·2025
62305 IHS4-100 responses and other IHS4 outcomes with the IL-17A- and IL-17F-inhibiting Nanobody sonelokimab in patients with moderate-to-severe hidradenitis suppurativa (HS): Week 24 results from the Phase 2 MIRA trial
Journal of the American Academy of Dermatology·2025
Safety of tralokinumab in patients with moderate-to-severe atopic dermatitis followed for up to 4.5 years: an integrated analysis of eight clinical trials
British Journal of Dermatology·2025· 4 citedOpen Access
0047 Abrocitinib reduces circulating, skin homing, and resident memory T-cells in atopic dermatitis samples in vitro and ex vivo, and disease flare severity in a humanized mouse model
Journal of Investigative Dermatology·2025
Lessons from TNF-α Inhibitor–Induced Alopecia Areata: Does TNF-α Operate as a Hair Follicle Immune Privilege Guardian under Inflammatory Conditions?
Journal of Investigative Dermatology·2025· 2 cited
Long-Term Safety and Efficacy of Tralokinumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis Treated for up to 6 Years
SKIN The Journal of Cutaneous Medicine·2025· 1 citedOpen Access
Efficacy and safety of mirikizumab in psoriasis: a systematic review and meta-analysis of randomized controlled trials
Inflammopharmacology·2025· 1 cited
Favourable response of Blaschko linear psoriasis to interleukin-23 inhibition
Skin Health and Disease·2025Open Access
Efficacy and Safety of Nemolizumab in Patients With Moderate to Severe Prurigo Nodularis
JAMA Dermatology·2024· 35 citedOpen Access
350 A significant pro-inflammatory role for IL-17F in dermal tunnels: Implications for therapeutic interventions in hidradenitis suppurativa (HS)
Journal of Investigative Dermatology·2024Open Access
52741 Efficacy of Abrocitinib Versus Dupilumab on Dermatitis in the Head-and-Neck Region of Patients With Moderate-To-Severe Atopic Dermatitis: A Post Hoc Analysis of the Phase 3 JADE DARE Study
Journal of the American Academy of Dermatology·2024· 1 citedOpen Access
page 1 of 37Next →

Frequent Co-authors

Kim Papp(16), Andrew Blauvelt(14), Richard G. Langley(13), Diamant Thaçi(10), Mark Lebwohl(8), C.E.M. Griffiths(8), Kenneth B. Gordon(7), C. Paul(6), Matthias Augustin(6), Tsen‐Fang Tsai(5), Ulrich Mrowietz(5), Alexander Nast(5), Catherine Smith(5), Philippe Szapary(4), Shu Li(4), Paolo Gisondi(4), April W. Armstrong(4), Yasmine Wasfi(4), Juliet N. Barker(4), Andreas Pinter(4)